Brief: Icecure's Prosense® Cryoablation System Receives Regulatory Approval In Switzerland For Indications Including Breast, Lung, Liver, And Kidney Cancer
18/11/2025 13:38
Icecure Medical Ltd ICCM.O: ICECURE'S PROSENSE® CRYOABLATION SYSTEM RECEIVES REGULATORY APPROVAL IN SWITZERLAND FOR INDICATIONS INCLUDING BREAST, LUNG, LIVER, AND KIDNEY CANCER Source text: ID:nPn2Cr1Zza Further company coverage: ICCM.O
Recent news on Icecure Medical
See all newsIcecure Medical Ltd reports results for the quarter ended June 30 - Earnings Summary
Israel's IceCure Medical H1 revenue rises on higher system, probe sales
Brief: Icecure Sio Petitions Nccn To Include Cryoablation In Breast Cancer Treatment Guidelines, Citing Icecure's FDA Clearance Of Prosense®
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:45 AM